Role of somatostatin analogues in the treatment of neuroendocrine tumors

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 13, Issue 1, 2015, Pages 109-117

  Narayanan, Sujata ^a   Kunz, Pamela L ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; OCTREOTIDE; PASIREOTIDE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ABDOMINAL CRAMP; ARTICLE; CANCER CONTROL; CANCER INHIBITION; CHOLELITHIASIS; DIARRHEA; FLATULENCE; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULINOMA; ISOTOPE LABELING; MULTICENTER STUDY (TOPIC); NAUSEA; NEUROENDOCRINE TUMOR; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEATORRHEA; TREATMENT OUTCOME; TUMOR GROWTH; ANALOGS AND DERIVATIVES; METABOLISM; NEUROENDOCRINE TUMORS; PATHOLOGY;

ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; NEUROENDOCRINE TUMORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 84921511812     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2015.0012     Document Type: Article

References (51)

1. Lawrence B, Gustafsson BI, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011;40:1-18, vii.
2. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-3072.
3. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 2010;21:1794-1803.
4. Mocellin S, Nitti D. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531). Ann Oncol 2013;24:3040-3044.
5. Rindi G AR, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman TF, Carneiro F, Hruban RH, Theise ND, eds. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon, France: International Agency for Research on Cancer (IARC); 2010:13.
6. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev 1995;16:427-442.
7. Reichlin S. Somatostatin. N Engl J Med 1983;309:1495-1501.
8. Larsson LI, Goltermann N, de Magistris L, et al. Somatostatin cell processes as pathways for paracrine secretion. Science 1979;205:1393-1395.
9. Nilsson O, Kolby L, Wangberg B, et al. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer 1998;77:632-637.
10. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996;334:246-254.
11. de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SW. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer 2003;10:451-458.
12. Fjallskog ML, Ludvigsen E, Stridsberg M, et al. Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol 2003;20:59-67.
13. Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010;31:169-188.
14. Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179:77-79.
15. Reichlin S. Secretion of somatostatin and its physiologic function. J Lab Clin Med 1987;109:320-326.
16. Thulin L, Samnegard H, Tyden G, et al. Efficacy of somatostatin in a patient with carcinoid syndrome. Lancet 1978;2:43.
17. Guillemin R. Peptides in the brain: the new endocrinology of the neuron. Science 1978;202:390-402.
18. Oberg K. Future aspects of somatostatin-receptor-mediated therapy. Neuroendocrinology 2004;80(Suppl 1):57-61.
19. Kidd M, Drozdov I, Joseph R, et al. Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer 2008;113:690-700.
20. Bruns C, Lewis I, Briner U, et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002;146:707-716.
21. Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30:1338-1347.
22. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273-282.
23. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999;17:600-606.
24. Bajetta E, Procopio G, Catena L, et al. Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a phase III study. Cancer 2006;107:2474-2481.
25. Ruszniewski P, Ish-Shalom S, Wymenga M, et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 2004;80:244-251.
26. Khan MS, El-Khouly F, Davies P, et al. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel). Aliment Pharmacol Ther 2011;34:235-242.
27. O'Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000;88:770-776.
28. Vinik A, Wolin E, Audry H, Gomez-Panzani E. ELECT: a phase 3 study of efficacy and safety of lanreotide autoge/depot (LAN) treatment for carcinoid syndrome in patient with neuroendocrine tuors (NETs) [abstract]. J Clin Oncol 2014;32(Suppl 3):Abstract 268.
29. Schmid HA, Schoeffter P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 2004;80(Suppl 1):47-50.
30. Wolin EM, Jarzab B, Eriksson B, et al. A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs [abstract]. J Clin Oncol 2013;31(Suppl):Abstract 4031.
31. Massimino K, Harrskog O, Pommier S, Pommier R. Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients. J Surg Oncol 2013;107:842-846.
32. Kulke MH, Shah MH, Benson AB, et al. NCCN Clinical Practice Guidelines in Oncology for Neuroendocrine Tumors. Version 1.2015. Available at NCCN.org. Accessed December 22, 2014.
33. Boyd AE, DeFord LL, Mares JE, et al. Improving the success rate of gluteal intramuscular injections. Pancreas 2013;42:878-882.
34. Strosberg JR, Benson AB, Huynh L, et al. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist 2014;19:930-936.
35. Shen C, Shih YC, Xu Y, Yao JC. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis. Cancer 2014;120:2039-2049.
36. Schally AV. Oncological applications of somatostatin analogues. Cancer Res 1988;48(24 Pt 1):6977-6985.
37. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006;17:1733-1742.
38. Lawnicka H, Stepien H, Wyczolkowska J, et al. Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture. Biochem Biophys Res Commun 2000;268:567-571.
39. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-4663.
40. Caplin M, Ruszniewski P, Pavel M, et al. Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: the CLARINET extension study [abstract]. J Clin Oncol 2014;32(Suppl):Abstract 4107.
41. Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004;15:966-973.
42. Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000;7:971-994.
43. Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2002;32:110-122.
44. De Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002;32:133-140.
45. Waldherr C, Pless M, Maecke HR, et al. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001;12:941-945.
46. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002;43:610-616.
47. Paganelli G, Bodei L, Handkiewicz Junak D, et al. 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 2002;66:393-398.
48. Bodei L, Cremonesi M, Zoboli S, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003;30:207-216.
49. Bushnell D, O'Dorisio T, Menda Y, et al. Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors. J Nucl Med 2003;44:1556-1560.
50. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-2130.
51. Wild D, Fani M, Fischer R, et al. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nulc Med 2014;55:1248-1252.